Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has issued an announcement.
MindBio Therapeutics Corp. has issued Restricted Stock Units (RSUs) to certain directors and staff as compensation, aligning their interests with the company’s goals as it advances to the next stage of clinical trials. This strategic move underscores MindBio’s commitment to redefining mental health treatment through scalable, accessible psychedelic medicine solutions, potentially impacting the treatment landscape and stakeholder engagement.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focusing on developing novel psychedelic-based medicines for mental health disorders. The company is committed to scientific rigor and patient accessibility, pioneering the regulated, take-home use of psychedelic medicines in clinical trials to provide safe, effective, and scalable treatments for conditions such as depression and anxiety.
Average Trading Volume: 114,640
Technical Sentiment Signal: Sell
Find detailed analytics on MBIO stock on TipRanks’ Stock Analysis page.